Viatris-Mylan 1st to Receive FDA Approval of Generic Restasis for Dry Eye

 Viatris Inc. (NASDAQ: VTRS) today announced that its subsidiary, Mylan Pharmaceuticals, Inc., has received approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Cyclosporine Ophthalmic Emulsion 0.05%, the first generic version of Allergan's Restasis®. There are no remaining legal or regulatory barriers, and the company is launching immediately.

https://www.biospace.com/article/releases/viatris-is-first-to-receive-fda-approval-of-generic-restasis-cyclosporine-ophthalmic-emulsion-0-05-percent-to-treat-dry-eye-disease/